NGeneBio Co., Ltd. announced that it has received KRW 20 billion in funding from SK Securities Co., Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, and other investors.
September 31, 2022
Share
On September 1, 2022, NGeneBio Co., Ltd. closed the transaction.
NGeneBio Co Ltd is a Korea-based company engaged in the manufacture and sale of precision diagnostic products. The Company's main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The Company also provides services such as genetic testing direct to customer(DTC) and personalized healthcare.
NGeneBio Co., Ltd. announced that it has received KRW 20 billion in funding from SK Securities Co., Ltd., Investment Arm, Shinhan Investment Corp., Investment Arm, and other investors.
NGENEBIO CO., LTD. 
